CFO interim
Atara Biotherapeutics, Inc. names Kevin G. Sarney interim CFO
Atara Biotherapeutics, Inc. reported in a Form 8-K filed June 26, 2026 that Kevin G. Sarney was named interim interim chief financial officer, effective June 26, 2026.
In the filing's words
On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc. (“CRCFO”), as interim chief financial officer, effective as of June 26, 2026. In connection with his appointment, Mr. Sarney will serve as the Company’s principal financial officer and principal accounting officer.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Atara Biotherapeutics, Inc. (ATRA) |
|---|---|
| Event | Interim |
| Incoming | Kevin G. Sarney |
| Title in the filing | interim chief financial officer |
| Effective | June 26, 2026 |
| 8-K filed | June 26, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Life Science Practice Leader, Charles River CFO, Inc. |
| SEC CIK | 0001604464 |
Atara Biotherapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed June 26, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Kevin G. Sarney? Send a correction with the primary source.